Regulatory News
Friday, November 11, 2016
BRIEF-Idera reports data from ongoing Phase 1 clinical trial of intratumoral IMO-2125
* Idera Pharmaceuticals reports translational data
supporting the mechanism of action of intratumoral IMO-2125 from
ongoing Phase 1 dose escalation in clinical trial in combination
with ipilimumab in...
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment